Alpibectir (BVL-GSK098)
Multi-drug resistant Tuberculosis (MDR-TB) and TB Meningitis
Phase 2Active
Key Facts
Indication
Multi-drug resistant Tuberculosis (MDR-TB) and TB Meningitis
Phase
Phase 2
Status
Active
Company
About BioVersys
BioVersys is a privately held, clinical-stage biopharmaceutical company dedicated to addressing the global threat of antimicrobial resistance (AMR). Its pipeline features innovative, first-in-class assets with novel modes of action, targeting WHO and CDC priority pathogens like carbapenem-resistant Acinetobacter baumannii (CRAB) and Staphylococcus aureus. Key programs include BV100, which is entering Phase 3 for CRAB infections, and Alpibectir, a potentiator for MDR-TB treatment currently in Phase 2b. The company operates from its Basel headquarters, leveraging a platform focused on transcriptional regulator inhibitory compounds (TRIC) to develop impactful anti-infectives.
View full company profile